Skip to main content
The Inyo Register
Click for weather forecast
Place a Classified Ad
View Full List
Standard & Poors 500
New York Composite
Updated: 4:15 PM EST, Dec 7, 2021
Add to My Watchlist
Stories about CLL
BeiGene Reports BTK Inhibitor Posts Better Results than the Competition
June 11, 2021
Beijing 's BeiGene presented positive interim results from Phase III trial that compared its BTK candidate to AbbVie's Imbruvica (ibrutinib). In the trial, BeiGene's Brukinsa® (zanubrutinib) produced a...
InnoCare Approved to Launch BTK Inhibitor for Three Indications in China
December 31, 2020
Beijing InnoCare Pharma reported China 's NMPA approved its BTK inhibitor for three indications: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). All...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions
Copyright © 2015 The Inyo Register | 1180 N Main St Ste 108 | Bishop, CA, 72104 | (760) 873-3535
All property rights for the entire contents of this publication shall be the property of The Inyo Register.
No part hereof may be reproduced without prior written consent.